Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026Score 9/3079% below fair value
$1.78−0.01 (-0.56%)
Close on Nov 13, 2026Market cap $19.34MP/E –Yield –
Aytu BioPharma gross margin
Gross margin is gross profit as a percentage of revenue.
Aytu BioPharma's gross margin for the twelve months ending Jun 30, 2026 was 64.0%. For fiscal 2026 it was 64.0%, against 69.0% the year before. The highest annual figure on record is 75.3% in fiscal 2024.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | 64.0% | −5.1 |
| FY2025 | Jun 30, 2025 | 69.0% | −6.2 |
| FY2024 | Jun 30, 2024 | 75.3% | +13.2 |
| FY2023 | Jun 30, 2023 | 62.0% | +8.0 |
| FY2022 | Jun 30, 2022 | 54.1% | +9.6 |
| FY2021 | Jun 30, 2021 | 44.5% | −25.5 |
| FY2020 | Jun 30, 2020 | 70.0% | +0.1 |
| FY2019 | Jun 30, 2019 | 69.9% | +25.9 |
| FY2018 | Jun 30, 2018 | 44.0% | −12.0 |
| FY2017 | Jun 30, 2017 | 56.0% | −6.6 |
| FY2016 | Jun 30, 2016 | 62.6% | −3.7 |
| FY2015 | Jun 30, 2015 | 66.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | 64.6% | −3.1 |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | 61.2% | −8.2 |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | 63.5% | −3.0 |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | 66.1% | −6.2 |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | 67.8% | −8.0 |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | 69.4% | −4.5 |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | 66.5% | −11.4 |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | 72.3% | −0.9 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | 75.7% | +15.3 |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | 73.9% | +17.8 |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | 77.9% | +12.1 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | 73.2% | +8.0 |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | 60.4% | +6.3 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | 56.1% | +3.6 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | 65.8% | +12.6 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | 65.2% | +8.3 |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | 54.1% | +6.0 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | 52.4% | +55.8 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | 53.2% | −5.5 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | 56.9% | −13.1 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | 48.1% | −16.2 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -3.4% | −78.8 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | 58.7% | −22.2 |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | 69.9% | −4.0 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | 64.3% | +2.2 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | 75.5% | +1.4 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | 80.9% | +10.2 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | 73.9% | +2.6 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | 62.2% | −11.8 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | 74.1% | +161.2 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | 70.7% | +7.4 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | 71.3% | −2.0 |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | 73.9% | +15.8 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -87.1% | −150.8 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | 63.3% | +32.8 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | 73.3% | +0.8 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | 58.2% | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | 63.7% | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | 30.6% | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | 72.5% | – |
See a number that looks wrong?